NYSE:ADCT ADC Therapeutics Q3 2026 Earnings Date & Estimates $1.42 -0.29 (-16.76%) As of 03:45 PM Eastern This is a fair market value price provided by Massive. Learn more. ADC Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. The conference call is scheduled for November 9, 2026 at 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeBefore Market OpensConference Call DateNovember 9, 2026Conference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ADC Therapeutics in Q3 2026ADC Therapeutics is expected to post earnings of -$0.21 per share on revenue of $18.69 million. In the same quarter a year earlier ADC Therapeutics reported -$0.30 per share on revenue of $16.43 million. ADC Therapeutics last reported on August 13, 2026, posting -$0.11 per share and beating the -$0.2160 consensus estimate. ADC Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.21Expected Revenue$18.69 millionPrior-Year EPS-$0.30Prior-Year Revenue$16.43 millionExpected Revenue Growth+13.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.11 (Beat by +$0.1060)Last Quarter Revenue$19.25 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report ADC Therapeutics Q3 2026 Earnings FAQ When does ADC Therapeutics report Q3 2026 earnings? ADC Therapeutics (NYSE:ADCT) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is ADC Therapeutics' Q3 2026 earnings call? ADC Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ADC Therapeutics? Analysts expect ADC Therapeutics to post earnings of -$0.21 per share for Q3 2026. How much revenue is ADC Therapeutics expected to report? The consensus revenue estimate for ADC Therapeutics is $18.69 million for Q3 2026. ADC Therapeutics Earnings HeadlinesFinancial Analysis: ADC Therapeutics (NYSE:ADCT) versus Kymera Therapeutics (NASDAQ:KYMR)October 13 at 4:59 AM | americanbankingnews.comSagimet Biosciences (NASDAQ:SGMT) versus ADC Therapeutics (NYSE:ADCT) Head to Head ContrastOctober 11 at 6:58 AM | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC SaysOctober 9, 2026 | finance.yahoo.comADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull ThesisOctober 9, 2026 | seekingalpha.comADC Therapeutics SA announced that it expects to receive $81.81 million in funding from Redmile Group, LLC, TCG Crossover Management, LLC, Nantahala Capital Management, LLC ...October 8, 2026 | marketscreener.comMSee More ADC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ADC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADC Therapeutics and other key companies, straight to your email. Email Address About ADC TherapeuticsADC Therapeutics (NYSE:ADCT) (NYSE: ADCT) is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC technology is designed to use antibodies to selectively deliver potent cytotoxic agents to cancer cells, with the goal of limiting exposure to healthy tissue. The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed at the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. ADC Therapeutics is also advancing a pipeline of investigational ADC candidates for hematologic malignancies and solid tumors. ADC Therapeutics was founded in 2011 and is headquartered in Lausanne, Switzerland, with operations and commercial activities supporting its oncology programs in the United States and other markets. The company’s research and development efforts are focused on expanding its ADC platform and developing additional targeted cancer therapies.View ADC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
